127 related articles for article (PubMed ID: 15791479)
1. Mutation analysis of B-RAF gene in human gliomas.
Basto D; Trovisco V; Lopes JM; Martins A; Pardal F; Soares P; Reis RM
Acta Neuropathol; 2005 Feb; 109(2):207-10. PubMed ID: 15791479
[TBL] [Abstract][Full Text] [Related]
2. RAF expression in human astrocytic tumors.
Hagemann C; Gloger J; Anacker J; Said HM; Gerngras S; Kühnel S; Meyer C; Rapp UR; Kämmerer U; Vordermark D; Flentje M; Roosen K; Vince GH
Int J Mol Med; 2009 Jan; 23(1):17-31. PubMed ID: 19082503
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
[TBL] [Abstract][Full Text] [Related]
4. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A
Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916
[TBL] [Abstract][Full Text] [Related]
5. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
6. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations.
Jeuken J; van den Broecke C; Gijsen S; Boots-Sprenger S; Wesseling P
Acta Neuropathol; 2007 Aug; 114(2):121-33. PubMed ID: 17588166
[TBL] [Abstract][Full Text] [Related]
7. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
[TBL] [Abstract][Full Text] [Related]
8. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
9. B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Jaworski M; Buchmann A; Bauer P; Riess O; Schwarz M
Oncogene; 2005 Feb; 24(7):1290-5. PubMed ID: 15592514
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
11. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
[TBL] [Abstract][Full Text] [Related]
13. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
[TBL] [Abstract][Full Text] [Related]
14. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
[TBL] [Abstract][Full Text] [Related]
15. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
[TBL] [Abstract][Full Text] [Related]
16. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
17. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.
Matos P; Oliveira C; Velho S; Gonçalves V; da Costa LT; Moyer MP; Seruca R; Jordan P
Gastroenterology; 2008 Sep; 135(3):899-906. PubMed ID: 18602919
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.
Tawbi H; Thomas D; Lucas DR; Biermann JS; Schuetze SM; Hart AL; Chugh R; Baker LH
Oncologist; 2008 Apr; 13(4):459-66. PubMed ID: 18448562
[TBL] [Abstract][Full Text] [Related]
19. Comparative transcriptome and proteome analysis of Ha-ras and B-raf mutated mouse liver tumors.
Rignall B; Ittrich C; Krause E; Appel KE; Buchmann A; Schwarz M
J Proteome Res; 2009 Aug; 8(8):3987-94. PubMed ID: 19476384
[TBL] [Abstract][Full Text] [Related]
20. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
